Cargando…

Appraisal of fungal infections during ECMO therapy

Detalles Bibliográficos
Autores principales:	Mongardon, Nicolas, Constant, Ophélie, Taccone, Fabio Silvio, Levesque, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989422/ https://www.ncbi.nlm.nih.gov/pubmed/29871652 http://dx.doi.org/10.1186/s13054-018-2082-1

Ejemplares similares

Candida bloodstream infection under veno-arterial ECMO therapy
por: de Roux, Quentin, et al.
Publicado: (2019)

Angiotensin II in ECMO patients: a word of caution
por: Antonucci, Elio, et al.
Publicado: (2019)

Thrombolysis for ECMO oxygenator thrombosis
por: Taccone, Fabio Silvio, et al.
Publicado: (2023)

Veno-venous ECMO during surgical repair of tracheal perforation: A case report
por: Antonacci, Filippo, et al.
Publicado: (2017)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

ECMO and the intensivist
por: Ghio, F E, et al.
Publicado: (2011)

Clinical feedback from experience with COVID-19: Specific considerations for extracorporeal membrane oxygenation
por: Fiore, Antonio, et al.
Publicado: (2020)

Cerebral oximetry during extracorporeal cardiopulmonary resuscitation
por: Taccone, Fabio Silvio, et al.
Publicado: (2013)

Clinical relevance and impact of Corynebacterium isolation in lower respiratory tract of critically ill patients requiring mechanical ventilation
por: Clariot, Simon, et al.
Publicado: (2020)

Early Findings after Implementation of Veno-Arteriovenous ECMO: A Multicenter European Experience
por: Blandino Ortiz, Aaron, et al.
Publicado: (2021)

Hybrid blood purification strategy in pediatric septic shock
por: Bottari, Gabriella, et al.
Publicado: (2016)

Extracorporeal endotoxin adsorbent therapy in the critically ill patients with COVID-19 during ECMO
por: Fu, Bao, et al.
Publicado: (2023)

Extracorporeal endotoxin adsorbent therapy in the critically ill patients with COVID-19 during ECMO
por: Fu, Bao, et al.
Publicado: (2023)

Angiotensin in ECMO patients with refractory shock
por: Ostermann, Marlies, et al.
Publicado: (2018)

Should ECMO be used in cardiogenic shock?
por: Gokalp, Orhan, et al.
Publicado: (2019)

Cytotoxic lesions of the corpus callosum (CLOCCs) associated with SARS-CoV-2 infection
por: Moreau, Anthony, et al.
Publicado: (2020)

Impact of CRRT in Patients with PARDS Treated with VV-ECMO
por: Redant, Sébastien, et al.
Publicado: (2021)

ECMO for COVID-19 patients in Europe and Israel
por: Lorusso, Roberto, et al.
Publicado: (2021)

ECMO and endogenous carboxyhemoglobin formation
por: Tripathi, Ravi S, et al.
Publicado: (2011)

Bivalirudin and post-cardiotomy ECMO: a word of caution
por: Ranucci, Marco
Publicado: (2012)

What is New in ECMO for COVID-19?
por: Furzan, Alberto, et al.
Publicado: (2023)

Normalizing the Abnormal: Hypoxemia in Venovenous ECMO
por: Ortoleva, Jamel P., et al.
Publicado: (2022)

Re: Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs (Friedrichson et al., Critical Care, January 2021)
por: Warren, Alex, et al.
Publicado: (2021)

Neurologic Injury in Patients With COVID-19 Who Receive VV-ECMO Therapy: A Cohort Study
por: Kannapadi, Nivedha V., et al.
Publicado: (2021)

Infection control on ECMO
por: Till, Judit N.
Publicado: (2017)

Veno-venous ECMO indications: more than respiratory support
por: Blandino Ortiz, Aaron, et al.
Publicado: (2019)

ECMO in paediatric septic shock: an urgent need for prospective trial
por: Beretta-Piccoli, Xavier, et al.
Publicado: (2020)

Choosing the right reference cohort for assessing outcome of venovenous ECMO
por: Supady, Alexander, et al.
Publicado: (2022)

Persistent Hypoxemia in COVID-19 Patients on ECMO: Keep Your Eyes on the Prize
por: Kopanczyk, Rafal, et al.
Publicado: (2022)

ECMO for ARDS due to COVID-19
por: Ñamendys-Silva, Silvio A.
Publicado: (2020)

Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
por: Honore, Patrick M., et al.
Publicado: (2020)

Postcardiotomy VA-ECMO for refractory cardiogenic shock
por: Charlesworth, Michael, et al.
Publicado: (2017)

Levosimendan for VA‐ECMO weaning: the silver lining
por: Kaddoura, Rasha, et al.
Publicado: (2021)

Possible significance of hemodynamic and immunomodulatory effects of early stress-dose steroids in cardiac arrest
por: Mentzelopoulos, Spyros D., et al.
Publicado: (2016)

Commentary: To ECMO or not to ECMO: That is the question
por: Worku, Berhane, et al.
Publicado: (2020)

Right Ventricular Dysfunction in COVID-19 ECMO—A Red Herring or the Real Deal?
por: Kopanczyk, Rafal, et al.
Publicado: (2022)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Impact of late administration of corticosteroids in COVID-19 ARDS
por: Mongardon, Nicolas, et al.
Publicado: (2020)

Does evolution of pre-ECMO conventional therapies affect the use of ECMO over the past decade in the regional ECMO centre in UK?
por: Najafi, N, et al.
Publicado: (2002)

Organizational characteristics: Effect on outcome of ICU COVID-19 patients in Belgium – Authors' reply
por: TACCONE, Fabio Silvio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6rq3msr52iuco5sms81ff3gqq2